Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide and Peripheral Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of type 2 diabetes within at least 6 months~* peripheral arterial disease documented within al least 1 year by doppler ultrasound, angio-CT or arteriography~* peripheral transcutaneous oxygen pressure between 30 and 49 mmHg on anterior and/or posterior tibial arteries~* Hba1c 6,5-8%~* treatment of diabetes with metformin, insulin and/or sulfonylurea~Exclusion Criteria:~* diagnosis of type 1 diabetes~* current treatment with GLP-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase -4 (DPP-4) inhibitors~* GLP-1RAs allergy or intolerance~* participation to other clinical studies~* history of pancreatitis, thyroid disease, diabetic gastroparesis or inflammatory bowel disease~* current or planned pregnancy~* acute myocardial infarction and/or acute cerebrovascular disease within 14 days from the screening visit~* planned revascularization procedure~* renal function with estimated glomerular filtration rate (eGFR) below 15 ml/min~* history of cancer and/or oncological treatment within 5 years from the screening visit~* current treatment with corticosteroids~* psychiatric or other clinical conditions which may interfere with the study

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide group (Type: EXPERIMENTAL): Patients in this arm will receive liraglutide, according to the current clinical practice.
- Control group (Type: OTHER): Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.

Based on this trial design, predict the completion outcome and termination type (if applicable).